11q13 1432
18Fluorodeoxyglucose SPECT 1424
18q 1562
1p/19q loss 1424
201Thallium SPECT 1424
5-aza-2′-deoxycytidine 1701
5-fluorouracil 13, 35, 131
5-FU 607
accidental poisoning 649
acquired immunodeficiency syndrome (AIDS) 642
activity 13
acute lymphoblastic leukaemia 1537
adenocarcinoma 118
adenovirus 555
adhesion 1497, 1545
adipose tissue 1028
adjuvant therapy 260, 266, 817, 1195
advanced breast cancer 667, 794, 1161
advanced gastric cancer 1642
advanced melanoma 581
aetiologic heterogeneity 123
aetiology 1269
affymetrix SNP array 1415
Africa 355
ageing 520
age-period-cohort analysis 398
age–period–cohort models 1269
Akt 1653
alcohol 378
amplicon 1439, 1689
anaemia 13, 1274, 1467
angiogenesis 1038, 1131, 1371, 1396
angiotensin converting enzyme (ACE) 67
angiotensinogen 67
anthracycline 571
antiangiogenic tumour therapy 272
anticancer drug cytotoxicity 906
antifolates 289, 677
antioxidant defence 525
antitumoral drug 197
antivascular agents 722
anus neoplasms 87
anxiety 435
apoptosis 35, 49, 282, 520, 869, 961, 1114, 1348, 1696
aromatase inhibitors 661
array-CGH 1439
Ashkenazi 1448
aspirin 1277
AT1, AT2 receptors 67
autocrine 322
axillary dissection 811
β-catenin 889
basal phenotype 616
Bcl-2 869, 1244, 1653
BCR/ABL 775
BER 239
biliary tract neoplasms 848
bioactive lipid signaling 1131
bioinformatics 425
biomarker variability 42
bioreductive drugs 1229
birth weight 1603
bisphosphonate 1354
bladder 1415
bladder cancer 289, 1234, 1354, 1455
body mass index 366
body weight 153
bone 782
bone markers 506
bone metastases 506, 1354
borderline tumors 1092
Borrmann 744
BRCA 914
BRCA1 515, 757, 1108
BRCA1 and BRCA2 801, 1448
BRCA2 515, 757
breast cancer 67, 107, 123, 339, 347, 385, 390, 435, 525, 616, 642, 653, 674, 683, 757, 801, 811, 914, 974, 1056, 1291, 1334, 1362, 1404, 1410, 1448, 1626, 1683
breast carcinoma 62, 393, 506
breast conserving surgery 1265
breast MRI 801
breast neoplasms 1689
breast screening 62, 1265
Burkina Faso 355
cadherin 1258, 1367
CagA 639
calcium 1582
Calman-Hine 979
camptothecins 906
cancer cachexia 1028
cancer incidence 233
cancer proteomics 425
cancer registration 593, 1576
cancer risk 986
cancer screening 112
cancer survival 146, 1576
cancer-specific survival 1076
cannabinoid 197
cap-dependent translation 955
capecitabine 27, 1195
carboplatin 1309
carcinoembryonic antigen (CEA) 218, 674
carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) 532
carcinoma of unknown primary 1309
carcinomas 1670
cardiotoxicity 571
carotenoids 406
case–control study 1288, 1586
caspase activated DNase 1696
caspases 49, 282
castration resistance 767
CD105 1683
CD24 339
CD70 298
CDKN2A/p16 1432
CEA cell adhesion molecule (CEACAM) 218
C/EBPα 1028
cell blocks technique 204
cell cycle 555, 1348
cell cycle arrest 869
cell cycle regulation 314
cellular differentiation 307, 485
cellular senescence 496
central nervous system 416
cerulenin 869
cervical adenocarcinoma 331
cervical cancer 226, 385, 1250, 1459
cervical intraepithelial neoplasia (CIN) 1459
cervical neoplasia 96, 1593
cervical screening 56
chemokine 210
chemoradiation 260
chemoradiotherapy 561, 710
chemosensitivity 1424
chemotherapeutic drugs 1038
chemotherapy 27, 266, 463, 485, 848, 862, 966, 1114, 1142, 1334, 1626, 1632
childhood cancer 571
children 102, 416, 571, 991
China 96, 1593
cholangiocarcinoma 532
chromosome arm 3q 331
chronic myeloid leukaemia 1136
cigarette smoking 374
cisplatin 475, 822, 1005, 1348, 1648
client preferences 1448
clinical practice guidelines 1490
clinical resistance 955
clinical services 974
clinical trials 1155, 1459, 1483
clodronate 272
Clostridium 1212
CML 775
cohort studies 112, 363, 366, 374, 385, 639, 934, 1277, 1280, 1579
colon 1415
colorectal adenocarcinoma 1637
colorectal cancer 6, 27, 35, 131, 239, 735, 841, 889, 921, 928, 979, 1047, 1101, 1239, 1277, 1321, 1367, 1419, 1525, 1562
colorectal liver metastases 21
colorectal neoplasms 13, 1195
computerised decision support 1490
conjugation 1212
construction 102
continual reassessment method 253
copy number 1087, 1415
core biopsy 62
cost analysis 6
cost-effectiveness 27, 801
COX-2 139, 1234
CPT-11 710
C-reactive protein 1076, 1234
cremophor-free 729
CRP 782
cryo ablation 896
c-Src 1410
CTLA-4 896
cured cells 1020
CXCR4 210
cytokeratin 20 (CK20) 218, 1258
cytokines 1568
cytology 56, 1070, 1250
cytotoxic T cell 1202
cytotoxicity 1038
D2-40 1362
Danish 146
DaunoXome 571
DCI cases 1576
DCIS 1410
delay 835
deletion 548
dendritic cell 896
deprivation 944
DES 107
desmocollin 1367
desmosome 1367
diagnosis 1321
diet 406, 1582
dietary factor 1586
digestive cancer 944
dihydropyrimidine dehydrogenase 607
discrete choice experiment 1448
distance 944
distant metastases 710
DNA damage 520, 1514
DNA fragmentation factor 1696
DNA methylation 541
DNA ploidy pattern 817
DNA repair gene 561
DNA topoisomerase 1 906
docetaxel 457
doxorubicin 282, 1342, 1663
drug combination 289
drug delivery system 601
drug resistance 961, 1537
E1A 555
E-4IB isothiocyanate 1348
early detection 331
early onset 1288
early-onset colorectal cancer 752
economic evaluation 1195
EGF 164
EGFR 172, 1070, 1390, 1483, 1525
EGFR targeting 722
elderly 1309
EMAP-II 735
EMMPRIN 1371
endocrine therapy 661
endoglin 1683
endometrial cancer 266, 385, 642, 1555, 1586
EPIC 406
epidemiology 87, 96, 102, 112, 118, 123, 649, 986, 1280, 1579, 1582, 1593
epidermal growth factor receptor (EGFR) 998
epigenetics 541
epirubicin 1005
epistasis 525
epoetin beta 1467
equivalence 435
ERBB2 1689
etiology 1274
Ets transcription factor 1404
Europe 378
ewing tumour 1326
excess cases 401
exclusive chemo-radiotherapy 705
exemestane 153
expression profiling 1092
extensive-stage small-cell lung cancer 1648
extrapolation 398
extraversion 146
familial 974, 1288
familial cancer 435
familial risk 1291
Fas 1244
fatty acid synthase 869
feasibility study 853
fibroblast growth factor receptor 4 1455
fibrosarcoma cells 1114
fine-needle aspiration cytology 62
fingerprint 1537
first-line therapy 131, 788, 998
follow-up 21
formulation 729
forskolin 775
G1-phase cyclin-dependent kinase 1514
galectin-3 204
gastrectomy 940
gastric cancer 118, 159, 406, 445, 639, 1504
gastric carcinoma 1371
gastric/GEJ cancer 450
gefitinib 172, 722, 998, 1070, 1390, 1483, 1504
gemcitabine 260, 289, 532, 587, 848, 1309
gene amplification 1432
gene expression 80, 928, 1056
gene polymorphisms 906
gene–gene interactions 525
genetic and epigenetic alterations 1101
genetic counselling 435, 1448
genetic susceptibility 1689
genetics 541, 1288
genital warts 1459
genotypes 355
germline mutations 752
gestational trophoblastic disease 1145
glioblastoma 862, 1155
glioblastoma multiforme 197
glioma 862
glioma cells 869
glucocorticoid 1537
green tea 371
growth 1603
GSK-3 1653
HapMap 1689
head and neck cancer 1432
health services researches 593
height 366, 1603
Helicobacter pylori 639, 744
hepatectomy 1050
hepatitis C virus 1598
hepatocellular carcinoma (HCC) 210, 853, 1050, 1379
HER2 1404, 1410, 1504
HER 2-positive metastatic breast cancer 788
hereditary cancer 1678
HIF-1 1
high risk 801
high-grade gliomas 991
histamine 1663
histology 123, 1180
HIV 1598
HIV-1 355
HIV-1 protease inhibitor 1653
HNPCC 1678
hnRNP K 921
Hodgkin's lymphoma 378
homoharringtonine 253
horizontal gene transfer 1696
hormonal therapy 153
hormone-refractory prostate cancer 457
HPV 355, 1384, 1432
HPV detection 56
HPV prevalence 226
HPV vaccine 226
human immunodeficiency virus (HIV) 642
human papillomavirus 96, 331, 1250, 1459, 1593
hybrid capture 2 1384
hyperbaric oxygen 862
hypermethylation 1108, 1701
hypotonic cisplatin treatment 717
hypoxia 307, 735, 928, 1013, 1212
ICD-10 649
ICD-9 649
ifosfamide 1342
imaging 21
imatinib 1013
immortalisation 496
immunohistochemistry 204, 322, 347, 616, 634, 921, 1410
immunotherapy 247, 1167, 1202, 1244, 1474
incidence 87, 91, 416, 1269
incidence trends 398
indoleamine 2,3-dioxygenase (IDO) 1555
inducible gene expression 289
induction chemotherapy 470, 705
infant 1274
infection 102
inflammation 1568
ING2 80
innate immunity 247
inoperable pancreatic cancer 1474
insulin receptor substrate 1220
Insulin receptor-isoform A 172
insulin-like growth factors 112, 1220
integration 1384
interferon-α 463
interleukin-10 1076
interleukin-2 463, 1167
interleukin-6 1076
internalisation 298
interphase fluorescence in situ hybridisation 331
interstitial fluid pressure 1013
intracellular activation 189
intrapleural chemotherapy 717
invasion 1396
irinotecan 131, 587, 1648
irinotecan-resistant 1637
Ki-67 1234
kinase inhibitors 955
Korea 639
LABC 1005
laparoscopic 6
laryngeal squamous cell carcinoma 314
Laurén 744
leptomeningeal dissemination 991
leucovorin 159
leukaemia 102, 253, 775, 1274
level-I dissection 811
level-III dissection 811
lipid 153
lipodomics 1131
liposomes 272, 822
liver 210, 1545
liver metastasis 1504, 1562
localised prostate cancer 1186
LOH 1562
loss of heterozygosity 515, 541
loss of imprinting 541
low-grade gliomas 1062
low-grade squamous intraepithelial lesions 1384
luminol 189
lung cancer 139, 607, 677, 1013, 1070, 1280, 1288
lung neoplasms 75, 1483
lymph node metastasis 75, 634, 1362, 1611
lymph nodes 841
lymphadenectomy 699
lymphangiogenesis 1362, 1611
lymphatic and vascular invasion 445
lymphatic endothelial cell proliferation (LECP) 1611
lymphatic vessel density (LVD) 1611
lymphocytes 520, 1545
lymphocytes apoptosis 735
M30 Apoptosense 42
M65 Elisa 42
macrophage depletion 272
MAD2 475
magnetic resonance imaging 416
malignant melanoma 91
malignant morphology 889
malignant pleural effusion 717
mammalian target of rapamycin (mTOR) 955
mathematical biology 1136
matrix metalloproteinase 7 (MMP7) 218
matrix metalloproteinases 506
MEK 475
melanoma 80, 181, 496, 829
mesothelioma 649
meta-analysis 112, 139
metallothionein 339
metastasectomy 691
metastasis 210, 425, 1396, 1419
metastatic renal cancer 463, 691
metastogenic phenotype 1101
methotrexate 1537
MGMT 1155
microarray 1092
microRNA 1415
microsatellite instability 1239
microvascular endothelium 1497
midostaurin 829
migration 1545
minichromosome maintenance proteins 314
minodronic acid 1354
mitochondria 1529
mitochondrial DNA 1087
mitomycin C 1229
mitosis–karyorrhexis index (MKI) 49
mitoxantrone 457
molecular subtypes 1334
monoclonal antibody proteomics 921
mortality 91, 107, 416, 940, 1321, 1632
motility 164, 1220
MSH6 752, 1678
MSI 1678
mTOR 1148
mucin 2 (MUC2) 218
multidisciplinary teams 979
multikinase inhibitor 581
multilevel Cox model 944
multiple basal cell carcinoma 548
multiple myeloma 782, 961
multiple primary malignancies 986
multiple tumours 390
muscle-invasive bladder cancer 561
mutations 757, 914, 998, 1070, 1390, 1529
MUTYH 239
MYH 239, 1239
N2-disease 470
N-acetylcysteine 35
naevus 496
nasopharyngeal neoplasm 1269
NBCCS 548
NCI-60 panel 906
NDRG1 307
neoadjuvant 710
neoadjuvant chemoradiation 1174
neoadjuvant chemotherapy 1683
neoplasms 416, 1180, 1579
nephrectomy 1076
neuroblastoma 49, 879
neuroendocrine carcinoma 1148
neuroleptic medication 934
neuroticism 146
NF1 233
NF-κB 247
NGF 322
nitroreductase 1212
NK105 601
non-Hodgkin's lymphoma 1598
non-small cell lung cancer (NSCLC) 470, 717, 817, 822, 966, 998, 1142, 1653
nonsteroidal anti-inflammatory drugs 363, 1277
normal breast 515
Norway 366
novel therapy 961
NQO1 1229
NQO2 1229
nutritional assessment 431
octreotide 853
oesophageal cancer 322, 634, 705, 835, 1174
oesophagectomy 940
oesophagus 118, 1180
oestrogen receptor alpha 339
oestrogen receptor-β isoforms 616
oestrogens 107
oligodendroglioma 1424
oncocytic cells 1529
oncogene 1439
oral cancer 363, 1396
oral contraceptives 385
orotate phosphoribosyl-transferase 607
orthotopic model 1354
OSI-7904L 450
osteopontin 634
osteosarcoma 1603
outcome 1326
ovarian cancer 385, 627, 642, 757, 1092, 1314
ovarian carcinoma 699, 1087
overdiagnosis 401
oxaliplatin 131, 848, 1195
oxaliplatin-resistant 1637
P14ARF 1670
p16 496
P16INK4A 1670
p27 regulation 1514
p53 35, 49, 496, 627
p53 mutation 1701
p53 target gene 1701
p75NTR 322
paclitaxel 159, 601, 729, 1005, 1642
palliative care 593, 966
pancreatic cancer 260, 307, 587
PATCHED 548
pathologic tumour-node-metastasis (pTNM) stage 1050
paxoral 794
PBSC 1326
PEA3 1404
pemetrexed 677
perceived needs 667
periostin 1396
persistent infection 1020
pharmacodynamics 450
pharmacokinetics 450, 677, 729
phase I 253, 571
phase II 450, 794, 1148
Phellinus linteus 282
phosphorylated EGFr 1525
photodynamic therapy 189
phototherapy 485
PI3K/Akt, drug resistance 1504
pilot clinical study 197
place of death 593
platinum complex 1514
pleural effusion 1390
PNA-LNA PCR clamp 1483
podoplanin 1362, 1611
polycomb 1202
polymer micelle 601
polymorphism 1047
population mixing 102
population-based 363, 393, 653, 934, 986, 1296
porphyrin 485
positron emission tomography 1174
PP2A 775
PPARδ 889
PPARγ 879
prediction 691
predictive markers 1683
preoperative diagnosis 204
primary health care 974, 1321
PRL-3 347
probability model 757
profiling 1439
prognosis 339, 506, 627, 634, 691, 835, 1062, 1081, 1371, 1419, 1455
prognostic factors 139, 347, 445, 782, 1186, 1296, 1555
progression 1371
progression-free survival (PFS) 1555
proliferation 616, 1081, 1220
prolonged temozolomide 1155
prophylactic vaccine 1459
(pro)renin 67
prospective cohort study 146, 371
prospective studies 233, 1277
prostate 1415
prostate cancer 164, 282, 371, 398, 401, 425, 767, 1081, 1582
proteasomes 961
protein degradation 961
protein kinase C 829
protein level 744
proteome 1379
proteomics 298
pS2 339
pS6 1148
PSA 401
pseudomyxoma peritonei 1258
PTP4A3 347
puberty 1603
pyrrolidinedithiocarbamate 35
quality of life 667, 683, 966, 1626
quantitative reverse-transcription polymerase chain reaction (QRT-PCR) 1062
quantitative RT–PCR 42
Rac 1081
radiation effects 390
radiation therapy 862
radiofrequency ablation 896
radiosensitiser 601
radiosensitivity 1
radiotherapy 266, 390, 1142
radon 1280
randomised clinical trial 266, 699
randomised controlled trial 433, 811, 817, 1005
randomised discontinuation trial 581
rapamycin 955
real-time PCR 1568
receptors 853
rectal cancer 710
regional treatment 1663
registries 653
regulatory T cell 896, 1202
relative survival 1296
renal cancer 1076, 1167
renal cell carcinoma 298, 374, 1244
reovirus oncolysis 1020
resistance 172, 661
resistance mechanisms 955
response 1174
retinoids 463
retinol 406
risk 363, 393, 914, 934, 1047
risk factors 642
road distance 944
ROS 1497
rosiglitazone 879
routine statistics 1576
RT–PCR 1326
rural 102
S-1 1637, 1642
safety 729
salvage surgery 1342
scintigraphy 853
Scotland 87
screening 801, 1250
screening mammography 1265
second cancer 393
second primary cancer 1142, 1291
secondary dissemination 991
SELDI 1379
selenium 674
sensitivity 1334
serum 1379
SET 775
sexual function 1626
signal transduction inhibitors 661
signalling adapter protein 1419
SIL 355
single nucleotide polymorphism 561, 1455, 1689
sirtuins 1056
Six1 1050
Smad4 1562
small intestinal cancers 1296
social class 1180
socio-economic deprivation 940
socioeconomic position 653
soft-tissue sarcomas 986, 1342, 1663
somatostatin 853
Sorafenib 581
specialisation 979
S-phase fraction 314
sphingosine-1-phosphate 1131
SPI-77 822
squamous cell carcinoma 87
SREBP-1c 1028
stability 42
stage migration 841
staging 653, 1180
standard gamble 683
STAT3 164
STK15 1047
stopping rules 253
stress 1579
stressful life events 1579
supplements 1582
supportive care 667
surgery 6, 699, 782, 1167
surgical resection 835
surgical trauma 1497
survival 91, 139, 561, 744, 966, 1050, 1145, 1167, 1234, 1314, 1467
Switzerland 1598
systematic review 139, 457
systems biology 425
T cells 181
t-AML 1108
tamoxifen 118, 153
targeted cancer therapy 1136
targeted drug delivery 189
targeted therapies 131, 661, 691, 767, 1525
TAV 1663
tegafur 27
telomerase 331
telomerase activity 1250
telomerase vaccine 1474
temsirolimus 1148
TGCT 475
The Netherlands 374
three-week schedule 1648
thymidylate synthase 607, 928
thyroid 1670
thyroid cancer 204, 366, 1529
Tiam1 1081
timing 835
TIMP-1 1114
tissue microarray 80
T-lymphocytes 1234
tobacco 378
tocopherol 406
toll-like receptors 247
topoisomerase II 1038
topoisomerase IIα 1334
toxicity 853
TP53 1432
TP53 mutation 1455
Tp73 isoforms 1062
transcription 555
transferrin 189
transformation 555
transplantation 181
trastuzumab 788, 1504
treatment duration 966
trends 1269, 1296
TrkA 322
tumour antigens 1202
tumour cell 1497
tumour cell contamination 1326
tumour immunity 181
tumour markers 21, 425
tumour microenvironment 1131
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 49
tumour regression 1020
tumour-associated macrophages 272
twins 520
type I insulin-like growth factor receptor 1220
typing 56
tyrosine kinase inhibitor 1483
UFT 159, 817
uranium miners 1280
uterine-sparing 1314
V600E BRAF 581
vaccination 896
validation 42
vascular endothelial growth factor (VEGF) 1013, 1611
vascular endothelial growth factor receptor-3 75
vascular endothelial growth factor-C 75
venous infiltration 1050
vessel 1
vimentin 1258
vinflunine 1161
vinorelbine 788
viral load 1384
virus-like particles 1459
vitamin D 1582
vitamin supplementation 677
vitronectin 1545
von Hippel–Lindau gene mutations 374
wartime 102
weekly administration 1005
weight loss 431
Wilms' tumour 541
ZD6126 722
zebularine 1701
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 95. Br J Cancer 95, 1718–1721 (2006). https://doi.org/10.1038/sj.bjc.6603541
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6603541